References
- Witjes JA, Bruins HM, Carrión A et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. 2022. Available from: https://uroweb.org/guidelines/muscle-invasive-and-metastatic-bladder-cancer
- Wild CP, Weiderpass E, Stewart BW et al. World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer; 2020. Available from: www.iarc.who.int/cards_page/world-cancer-report/
- World Health Organization. Bladder fact sheet. 2020. Available from: https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf
- Robert Koch-Institut. Cancer in Germany 2019/2020. Berlin, Germany; 2021. Available from: www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_inhalt.html
- National Cancer Institute. Cancer Stat Facts: Bladder Cancer. Bethesda, MD; 2022. Available from: https://seer.cancer.gov/statfacts/html/urinb.html
- de Wit M, Bauernhofer T, Bokemeyer C et al. Leitlinie Blasenkarzinom (Urothelkarzinom). Berlin: DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.; 2017. Available from: https://repository.publisso.de/resource/frl:6419224/data
- Fisher MD, Shenolikar R, Miller PJ et al. Treatment patterns and outcomes in stage IV bladder cancer in a community oncology setting: 2008–2015. Clin. Genitourin. Cancer 2018;16(6):e1171–e1179.
- Aly A, Johnson C, Yang S et al. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma. J. Med. Econ. 2019;22(7):662–670.
- Cheeseman S, Thompson M, Sopwith W et al. Current treatment and outcomes benchmark for locally advanced or metastatic urothelial cancer from a large UK-based single centre. Front. Oncol. 2020;10:167.
- Niegisch G, Gerullis H, Lin SW et al. A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany. J. Cancer 2018;9(8):1337–1348.
- ClinicalTrials.gov. Study of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy alone in urothelial carcinoma (MK-3475-361/KEYNOTE-361). Bethesda, MD: National Library of Medicine, US; 2021 [ updated 2022 Oct 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT02853305
- ClinicalTrials.gov. Study of atezolizumab as monotherapy and in combination with platinum-based chemotherapy in participants with untreated locally advanced or metastatic urothelial carcinoma (IMvigor130). Bethesda, MD: National Library of Medicine, US; 2016 [ updated 2022 Oct 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT02807636
- Powles T, Bellmunt J, Comperat E et al. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2021;33(3):244–258.
- Institute for Quality and Efficiency in Health Care (IQWiG). Atezolizumab (Urothelkarzinom nach Chemotherapie) - Nutzenbewertung gemäß § 35a SGB V. Cologne, Germany; 2017. Available from: www.iqwig.de/download/a17-52_atezolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
- Institute for Quality and Efficiency in Health Care (IQWiG). Pembrolizumab (Urothelkarzinom Erstlinientherapie) - Nutzenbewertung gemäß § 35a SGB V. Cologne, Germany; 2017. Available from: www.iqwig.de/download/a21-34_pembrolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
- Institute for Quality and Efficiency in Health Care (IQWiG). Atezolizumab (Urothelkarzinom Erstlinientherapie) – Nutzenbewertung gemäß § 35a SGB V. Cologne, Germany; 2017. Available from: www.iqwig.de/download/a17-51_atezolizumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
- Institute for Quality and Efficiency in Health Care (IQWiG). Nivolumab (Urothelkarzinom) – Nutzenbewertung gemäß § 35a SGB V. Cologne, Germany; 2017. Available from: www.iqwig.de/download/a17-29_nivolumab_nutzenbewertung-35a-sgb-v_v1-0.pdf?rev=117386
- Institute for Quality and Efficiency in Health Care (IQWiG). Nivolumab (Urothelkarzinom, adjuvant) – Nutzenbewertung gemäß § 35a SGB V. Cologne, Germany; 2022. Available from: www.iqwig.de/download/a22-53_nivolumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
- Cathomas R, Lorch A, Bruins HM et al. The 2021 Updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur. Urol. 2021;81(1):95–103.
- Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 2.0. 2020. Available from: www.leitlinienprogramm-onkologie.de/leitlinien/harnblasenkarzinom/
- Institute for Quality and Efficiency in Health Care (IQWiG). Avelumab (Urothelkarzinom) – Nutzenbewertung gemäß § 35a SGB V. Cologne, Germany; 2021. Available from: www.iqwig.de/download/a21-23_avelumab_nutzenbewertung-35a-sgb-v_v1-0.pdf
- Powles T, Park SH, Voog E et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 2020;383(13):1218–1230.
- Bavencio (avelumab). Summary of product characteristics. Merck Europe B.V., Amsterdam, Netherlands, an affiliate of Merck KGaA; 2023.
- Institute for Quality and Efficiency in Health Care (IQWiG). Enfortumab Vedotin (Urothelkarzinom) – Nutzenbewertung gemäß § 35a SGB V. Cologne, Germany; 2022. Available from: www.iqwig.de/download/a22-61_enfortumab-vedotin_nutzenbewertung-35a-sgb-v_v1-0.pdf
- Kearney M, Zhang L, Hubscher E et al. Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis. Future Oncol. 2023: Epub Aug 1.
- Dinan MA, Georgieva MV, Li Y et al. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012. J. Geriatr. Oncol. 2021;12(2):298–304.
- Ward MM, Ulrich F, Matthews K et al. Who does not receive treatment for cancer? J. Oncol. Pract. 2013;9(1):20–26.
- Fernandez-Castilla B, Aloe AM, Declercq L et al. Concealed correlations meta-analysis: a new method for synthesizing standardized regression coefficients. Behav. Res. Methods 2019;51(1):316–331.
- Harbord RM, Higgins JPT. Meta-regression in stata. Stata J. 2008;8(4):493–519.
- Davies FJ, Knott C, Kerr C et al. Utilising Public Health England datasets to establish a standing cohort of patients with metastatic bladder cancer: initial results and algorithm defining disease progression. Value Health 2020;23:S480–S481.
- Knott C, Kearney M, Mahmoudpour H et al. Factors associated with the receipt of systemic treatment (tx) for metastatic urothelial carcinoma (mUC) in England. Ann. Oncol. 2022;33:S1338.
- Tariman JD, Doorenbos A, Schepp KG et al. Patient, physician and contextual factors are influential in the treatment decision making of older adults newly diagnosed with symptomatic myeloma. Cancer Treat. Commun. 2014;2(2–3):34–47.
- Kwon WA, Seo HK. Optimizing frontline therapy in advanced urothelial cancer. Transl. Androl. Urol. 2020;9(3):983–985.
- Geynisman DM, Broughton E, Hao Y et al. Real-world treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in the United States. Urol. Oncol. 2022;40(5):195.e1–195.e11.
- Maraz AC, Nagy B, Macher T et al. Nationwide study of real-world treatment patterns and clinical outcomes in patients with metastatic urothelial carcinoma in Hungary. Adv Ther. 2023;40:(12) 5475–5488.
- Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1. Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF; 2016. Available from: http://leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Blasenkarzinom/LL_Harnblasenkarzinom_Langversion_1.1.pdf
- Milowsky MI, Rumble RB, Booth CM et al. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J. Clin. Oncol. 2016;34(16):1945–1952.
- Jensen JB, Hauberg D, Hjortsø MD et al. Treatment pattern and overall survival among patients with locally advanced or metastatic urothelial carcinoma – Results from a complete nationwide unselected real-world registry study in Denmark from 2010 to 2017. Ann. Oncol. 2021;32:S716.
- Jodon G, Fischer SM, Kessler ER. Treatment of urothelial cancer in elderly patients: focus on immune checkpoint inhibitors. Drugs Aging 2018;35(5):409–421.
- Nishiyama N, Kobayashi T, Narita S et al. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. J. Geriatr. Oncol. 2022;13(1):88–93.
- Hartmann J, Weidmann C, Biehle R. [Validation of SHI claims data exemplified by gender-specific diagnoses]. Gesundheitswesen. 2016;78(10):e53–e58.
- Langner I, Ohlmeier C, Zeeb H et al. Individual mortality information in the German Pharmacoepidemiological Research Database (GePaRD): a validation study using a record linkage with a large cancer registry. BMJ Open 2019;9(7):e028223.
- Niegisch G, Grimm M-O, Hardtstock F et al. Treatment patterns, indicators of receiving systemic treatment, and clinical outcomes in metastatic urothelial carcinoma: a retrospective analysis of real-world data in Germany. J. Clin. Oncol. 2023;41(Suppl. 6): Abstract 464.
- Niegisch G, Kearney M, Krieger J et al. Factors associated with not receiving systemic treatment (tx) in patients (pts) with metastatic urothelial carcinoma (mUC): results of a retrospective observational study in Germany. Ann. Oncol. 2023;34(Suppl. 2):S1215 ( Abstract 2386P).